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Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of 
a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on 
highly active antiretroviral therapy (HAART).
Design: Prospective, multicenter, study.
Methods: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz 
(EFV) or lamivudine (3TC) + TDF + EFV and with a HIV-RNA  50 copies/mL were switched 
to the single-pill fixed-dose regimen (FDR) of FTC + TDF + EFV. Data were collected with 
SF-36 using visual analog scales. Results of the final (6 months) primary as-treated analysis 
are reported.
Results: 212 patients (77.4% males) of mean age 45.8 years were enrolled; 202 completed 
the study. One month post switch to FDR the adherence rate increased significantly to 96.1% 
from a baseline value of 93.8% (P  0.01). The increase was steadily maintained throughout 
the study (96.2% at 6 months). QoL improved over time from 68.8% to 72.7% (P = 0.042) 
as well, and was significantly associated with the perception of health status, presence of 
adverse events (AEs) and number of reported AEs (P  0.0001). QoL significantly influenced 
 adherence (P  0.0001). During FDR use the mean CD4 count increased from 556 to 605 
cells/µL (P  0.0001). At the end of follow-up 98% of patients maintained HIV-RNA level 
 50 copies/mL and 100% 400 copies/mL. Four patients stopped therapy because they were 
lost to follow-up and 6 because of AEs (insomnia/nervousness 4, allergy 1, difficulties swal-
lowing pills 1).
Conclusion: By substituting a one-pill once-a-day HAART, we observed an improvement of 
both adherence and QoL while maintaining high virologic and immunologic efficacy. HAART 
simplicity is an added value that favors adherence and may improve long-term success.
Keywords: EFV/FTC/TDF, single-pill regimen, once-daily antiretroviral regimen, adherence, 
QoL, patient preferences
Introduction
Adherence is a well-known problem in medicine. Especially in chronic, non-
 symptomatic diseases, keeping to the prescribed treatment has proven difficult for 
patients.1 For HIV-infected patients on highly active antiretroviral therapy (HAART), 
adherence is of outmost importance. Poor adherence may lead to treatment failure, 
selection of viral mutations and development of drug resistance.2,3 On the basis of 
earlier studies, an adherence level of 95% or more seems necessary to prevent viro-
logic failure;4 more recent experience has shown that durable viral suppression can be 
achieved by using regimens requiring lower adherence rates5–7 and that the relationship 
between adherence and the development of resistance differs by drug class.8–10
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Adherence can be considered an ever-changing and 
 adapting process influenced by socio-economic, health-
related, treatment-related, and behavior-related factors.11–13
In the past, several studies have shown how treatment 
simplification strategies could enhance patients’ adherence to 
HAART.14–18 Although it has been postulated that this type of 
intervention acts through an improvement of patients’ quality 
of life (QoL), a few studies have specifically addressed the 
relationship between QoL and adherence.11,19,20
ADONE (ADherence to ONE pill) is a qualitative study 
mainly intended to evaluate patient-oriented variables. 
Qualitative studies focus on the meaning people give to 
situations or events and are helpful to elucidate the pro-
cesses and the interactions of different factors playing a role 
in determining adherence rates. In this trial we evaluated 
how therapy simplification could affect adherence, QoL 
and subjective perception of health status and how these 
variables did influence one another.
Materials and methods
ADONE is multicenter, open-label, comparative, prospective 
study with a within-patient analysis. The study was not 
intended to verify the effect of a single drug but to study the 
advantages of a switch strategy in terms of patients’ oriented 
endpoints. The trial was conducted in 6 reference Italian 
Centers between March 2008 and April 2009.
Consecutive patients on a stable HAART and with a 
HIV-RNA level below the detection limit of 50 copies/mL 
could be enrolled. To be eligible, patients must have been on 
a HAART regimen based on the association of lamivudine/
emtricitabine + tenofovir (3TC/FTC + TDF) either as 
single molecules or as a fixed-dose combination (FDC) 
plus efavirenz (EFV). 3TC and FTC, due to their phar-
macokinetic and pharmacodynamic characteristics, were 
considered interchangeable.21 All patients were switched 
to a new regimen containing exactly the same active sub-
stances (FTC + TDF + EFV) but all in a FDC single pill. 
Patients, therefore, did not change their therapy in terms 
of active molecules or doses of the same molecules, but 
simply reduced the daily number of pills in their regimen 
from 3 or 2 to 1.
The main objective of the study was to verify if simpli-
fication of the antiretroviral regimen, measured as the mere 
reduction of pill burden, might affect patients’ adherence 
rate. The primary evaluation was based on an AT (as treated) 
approach assuming as the end-point the variation of adher-
ence rate at the end of the follow-up period compared to the 
respective baseline value.
Secondary objectives of the study were to verify the effect 
of the simplification strategy on QoL, to verify patients’ 
 preferences, to verify how adherence and QoL could change 
over time, and to establish virologic and immunologic 
 outcomes of the simplified regimen.
The secondary objectives of the study were mainly 
intended to be evaluated in a descriptive form. However, 
the variation of QoL and patients’ preferences were linked 
to the variation of adherence and to the virologic outcome 
of therapy, and inferential analysis was performed on these 
relationships.
All patient-related variables were collected at the moment 
of treatment switch and 1, 2, 4 and 6 months after the switch 
by means of a self-reported questionnaire based on a modified 
version of Medical Outcomes Study Short-Form Health Survey 
(SF-36).22 To collect data, we used a visual analog scale (VAS) 
based on a 100 mm horizontal line. A VAS is a sensitive instru-
ment to collect patients’ perception of descriptive terms widely 
used in medicine23 and validated for the assessment of adherence 
to HAART24 and for the study of QoL25 in HIV patients.
The instrument was non-judgmental and was explained 
and administered in a confidential manner by a trained 
 registered nurse.
Adherence was investigated with 4 separate questions 
considering 2 different recall periods: last month and last 
week. For each period patients were asked to report the 
proportion of doses taken and the proportion of doses taken 
with respect to the daily timing (±2 hours). In both cases a 
VAS scale was used to collect data.
Analysis of QoL was based on 3 groups of questions 
exploring limitations to: everyday social and work activities 
induced by either emotional of physical status; how much 
time in the past 4 weeks the patients experienced positive 
(eg, feeling full of life, feeling happy) or negative (feeling 
nervous, feeling worn-out) situations; and how true or false 
were statements investigating the current attitude and future 
concerns about their health status (eg, I seem to get sick 
more easily than other people, I am as healthy as anyone 
I know, I expect my health to get worse). A final QoL sum-
mary score was computed taking into account responses to 
all these items. An higher value indicated a better QoL.
A further question exploring the current perception and 
judgment of their health status was asked.
The presence/occurrence and severity of subjective symp-
toms were addressed by asking patients to report and grade 
any symptom experienced in the last 4 weeks using a 20-item 
list. The following symptom categories were addressed: 
gastrointestinal symptoms (bloating, pain in the stomach, 
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nausea and vomiting, diarrhea or loose bowel movements); 
respiratory symptoms (dyspnea); neurological symptoms 
(peripheral neuropathy, dizziness, muscle or joint pain); 
psychological discomfort (change in mood, problems having 
sex, changes in sleep pattern, trouble remembering, changes 
of body appearance); constitutional symptoms (fever, head-
ache, fatigue, loss of appetite, weight loss or wasting); and 
allergy symptoms (rash, skin and hair problems). Symptoms 
were analyzed individually and collectively.
Patients’ preferences and judgment of HAART was 
investigated by asking patients to quantify their personal 
judgment of the new therapy compared to the previous one in 
relation to 4 items: tolerability, convenience, simplicity and 
potency. A value of 50% indicated indifference, higher values 
a preference for the FDR, while lower values were indicative 
of a preference for the previous HAART regimen.
At baseline and 1, 2, 4 and 6 months after switching 
HAART, patients were tested for the occurrence of adverse 
events, hematological and chemical laboratory tests were 
performed, and patients were also tested for routine sur-
rogate markers of HIV infection (HIV-RNA and CD4 T-cell 
counts).
The study was powered to evaluate superiority of the 
simplified regimen as compared to the regimen at baseline. 
Assuming a baseline mean adherence rate of 93% with a 
standard deviation of 11%, a sample size of 154 patients 
was calculated to have 80% power to detect a difference in 
adherence proportion of 0.025 (eg, baseline mean of 0.930 
and a post-baseline mean of 0.955), assuming a standard 
deviation of difference of 0.110, and using a paired t-test 
with a 0.05 two-sided significance level. Being the primary 
analysis based on as treated approach, the sample size was 
adjusted to 180 patients based on an anticipated drop-out 
rate of 15%.
The primary analysis was based on a per protocol 
approach (AT). Patients were counted in this analysis if they 
completed the 6-month follow-up. A secondary analysis was 
performed according to the intention-to-treat non-completer 
(ITT NC) = failure approach. In this case all enrolled patients 
were included but patients not continuing the defined program 
for any reason were considered as failures. Each patient 
served as his or her own control.
Descriptive results are presented as proportions, means, 
range or 95% confidence intervals (CI). Inferential statistics 
using either parametric or non-parametric tests were used, 
as appropriate. Chi-square or Fisher’s exact test were used 
to analyze categorical variables; ANOVA and Student’s 
t-test were used for continuous variables unless they are not 
normally distributed, in which case the Mann–Whitney U 
tests or Wilcoxon signed rank test were used. Analysis of 
variance was used to explore the effect of multiple variables 
on specific outcomes.
All cited P values are 2-sided. All analyses were 
 performed with the SPSS statistical software package for 
Windows, version 13.0.
The study was approved by each site’s institutional review 
board. Appropriate informed consent was obtained from 
each participant and the clinical research was conducted 
in accordance with guidelines for the protection of human 
subjects.
Results
Two-hundred and twelve patients were enrolled and 202 
completed the study. The enrolled subjects had a mean 
age of 45.8 years (range 28–75 years) and 77.4% of them 
were males. Most had acquired HIV through heterosexual 
contacts (43.9%), while homosexual sex was a risk factor 
in 39.2% and intravenous drug use in 15.6%. Other risk 
factors for transmission counted for the remaining 1.4% 
of cases. A previous diagnosis of AIDS, according to the 
US Centers for Disease Control and Prevention (CDC) 
1993 revised classification system for HIV infection,26 was 
present in 21.7% of subjects. Patients had been receiving 
combination antiretroviral therapy for a mean of 5.7 years 
(range 0.2 to 13.5 years) and had been on their current 
HAART for a mean of 2.1 years (range 0.2–6.8 years). 
Overall, the mean number of HAART regimens the patients 
were exposed to was 2.4 (range 1–13), but 47.1% of sub-
jects were on their first therapeutic regimen. Baseline CD4 
T-cell counts ranged from 30 to 1989 cells/µL (mean 556 
cells/µL) and in all cases plasma HIV-RNA was below the 
limit of detection of 50 copies/mL.
Adherence
As expected, baseline adherence rates were high in patients 
fully responding to their therapy. The number of doses taken in 
the last month or in the last week were close to 97% and these 
values declined between 93% and 94% when dose timing was 
included in the question. Nevertheless, the simple switch to the 
FDC induced a sharp increase in adherence levels (Figure 1) 
that after a month were invariably significantly (P  0.001) 
higher. Over time the increase in adherence rates was main-
tained although partially reduced. At the end of the follow up 
the doses taken over the previous months increased by 1.1% 
(P = 0.01); the doses taken in the same period of time with 
respect to the dosing schedule increased by 2.3% (P = 0.002); 
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those taken in the last week increased by 0.6% (P = 0.116); 
and those taken in the last week with respect to the dosing 
timing increased by 2.4% (P = 0.009) (Figure 1).
Perception of health status
When actively asked, a relevant proportion of patients 
reported several symptoms that could be related to the taking 
of antiretroviral agents (Figure 2). Most patients (56.1%) 
reported the presence of fatigue, while symptoms indicated 
by between 40% and 50% of patients included: muscles 
aches, sleep abnormalities, changes in body shape, diarrhea, 
problems with having sex, sadness or depression, nervousness 
or anxiety. Over time, the proportion of patients not reporting 
any symptoms significantly (P  0.0001) improved, changing 
91
92
93
94
95
96
97
98
99
100
         
A
dh
er
en
ce
0
T0 T1 T2 T4 T6 T0 T1 T2 T4
Doses last month Doses last month right time Doses last time Doses last week right time
T6 T0 T1 T2 T4 T6 T0 T1 T2 T4 T6
Figure 1 Self-reported adherence rates at different time points (T expressed in months) according to the specific recall periods and eventual dosing timing.
Notes: The Y axis represents the indication on the VAS scale and can be regarded as a percentage. Data are expressed as means and 95% confidence intervals.
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Figure 2 Baseline proportion of patients indicating the presence of specific symptoms possibly related to HAART. All symptoms were actively investigated by means of a 
structured questionnaire and patients were asked to grade the discomfort each symptom caused (VAS scale).
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from 9.9% (at baseline) to 30.7%, 6 months after the switch 
to the FDC. The number of symptoms each patient reported 
significantly (P = 0.018) decreased, too. On the contrary, 
among patients reporting a given symptom, the perception of 
discomfort and the grading of it was rather stable over time. 
The presence and number of reported symptoms was strictly 
correlated (P  0.0001) with the perception of health status 
by each patient (Figure 3) and how patients perceived their 
health status was a significant determinant of how subjects 
judged their limitations to everyday social and work activi-
ties; how much time in the past 4 weeks they experienced 
positive (eg, feeling full of life, feeling happy) or negative 
(feeling nervous, feeling worn-out) situations; and how true 
or false were statements investigating the current attitude and 
future concerns about their health status (P  0.0001). Uni-
variate analysis indicated that several other variables could 
influence perception of health status. The mean perception 
was lower in heterosexuals (75.9%) and in intravenous 
drug users (72.9%) and higher in men having sex with men 
(81.9%) or in patients with other risk factors for HIV infec-
tion (92.6%) (P = 0.003) and it was also correlated with the 
length of HAART (P = 0.031). However, when entered in a 
multivariate model, only the reported symptoms retained a 
strong statistical significance (P  0.0001).
Quality of life
The various components of the QoL evaluation, although not 
always to a significant extent, invariably improved over time 
after the therapeutic switch. Limitations to everyday social 
and work activities declined from a baseline value of 17.3% 
(95% CI 14.3 to 20.3) to 16.5% (95% CI 13.7 to 19.3) after 
6 months; the presence of positive feelings such as being 
full of life or happy increased from 67.8% of the time (95% 
CI 64.3 to 71.4) at baseline to 70.2% (95% CI 70.0 to 73.4) 
after 6 months, while time with negative feelings (nervous 
or worn-out) was reduced from 40.3% (95% CI 37.0 to 
43.6) to 31.5% (95% CI 28.2 to 34.8) (P  0.0001). Patients 
worried less about their current health status and were less 
concerned about the risk of it deteriorating in the future. On 
a scale with the most negative judgment equal to 100 and 
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Figure 3 Influence of the presence and number of symptoms possibly related to HAART on the perception of health status at baseline. Box-plot analysis reporting median, 
interquartile range, 95% CI and outliers.
Abbreviation: AEs, adverse events.
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the best possible equal to 0, their evaluation was 34.4 (95% 
CI 31.3 to 37.5) at baseline and 31.5 after 6 months (95% CI 
28.3 to 34.6). As a consequence the overall evaluation of QoL 
significantly (P = 0.042) increased over time from a baseline 
value of 68.8 (95% CI from 67.7 to 70.0) to a value of 72.7 
(95% CI 71.5 to 73.8) after 6 months (Figure 4). QoL was 
strictly related to the perception of health status and to the 
presence of symptoms (P  0.0001), too.
QoL levels significantly influenced adherence rates 
(P  0.0001) (Figure 5). Patients in the lowest percentiles 
of QoL took 92.9% of doses (95% CI 83.4 to 100.0) in the 
last month; the doses taken in the same period of time with 
respect to the dosing schedule were 82.6% (95% CI 66.0 
to 99.1); those taken in the last week were 94.8% (95% CI 
87.9 to 99.7); and those taken in the last week with respect 
to the dosing timing were 85.2% (95% CI 72.8 to 97.5); the 
equivalent figures in patients in the highest percentiles were 
98.5 (95% CI 98.3 to 99.1); 97.3% (95% CI 92.9 to 96.4); 
98.6% (95% CI 98.1 to 99.1); and 97.7% (95% CI 96.2 to 
99.2), respectively.
Patients’ preferences
The comparative evaluation of the HAART regimen based 
on the use of single drug pills or on the FDC favored the last 
one in terms of patients’ preferences concerning tolerability, 
convenience and simplicity. The preference was evident 
1 month after the switch, but steadily increased over time 
(Figure 6) for all the considered characteristics of HAART. Of 
note, patients previously treated with lamivudine (thus receiv-
ing a regimen based on 3 pills) reported a higher preference 
rate for the FDC than those treated with emtricitabine (2 pills 
regimen because of the FDC emtricitabine/tenofovir). This 
difference was constant over time and expressed for all the 
characteristics, but was not statistically significant. However, 
the study was not powered to detect such a difference.
Interestingly, the patients’ preference were in favor of 
the FDC in terms of efficacy, too (Figure 6).
Immunologic response, virologic 
efficacy, tolerability
Although the mean baseline CD4 count was fairly elevated in 
our patients, a steady increase of CD4 cells was observed over 
time (Figure 7, panel A). At any time point the intra-patients 
analysis yielded a statistically significant result (P  0.001). 
After 6 months the mean CD4 increase was 49 cells/µL.
Virologic response to HAART was maintained through-
out the study. At 6 months according to the AT approach, 
100% of patients were below a HIV-RNA threshold of 400 
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copies/mL (Figure 7, panel B). Using a 50 copies/mL limit, 
98% of patients still presented a positive response. All the 
virologic rebounds we observed during the study period 
were transient viral blips of low intensity not present in suc-
cessive HIV-RNA determinations. Furthermore adherence 
rates in patients presenting transient HIV-RNA elevations 
were even higher (doses taken in the last month 97.9%, 95% 
CI 96.2 to 99.7) than those of patients steadily maintaining 
viral suppression (97.6%, 95% CI 97.2 to 97.9). Similarly 
to these results, the ITT NC analysis revealed a positive 
response below 400 copies/mL in 95.3% and below 50 
copies/mL in 93.4% of patients at 6 months.
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Figure 5 Influence of quality of life on adherence. Box-plot analysis reporting median, interquartile range, and outliers.
Abbreviation: QoL, quality of life.
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Note: Statistics refers to differences observed during the FDC use (from 1 month versus 6 months after the switch).
Patient Preference and Adherence 2010:4122
Airoldi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Six patients left the trial because of adverse events (AEs). 
In 4 cases CNS symptoms were involved (insomnia, altered 
dreams, nervousness), 1 patient presented a skin rash and 1 
patient had difficulties in swallowing the pills. All of these 
re-started their previous HAART regimen without any fur-
ther event. Four more patients stopped the trial because they 
moved to other centers.
Discussion
The complexity of medication regimens is often cited as one 
of the most important adherence barriers to HAART. Several 
surveys and cohort studies have shown that a number of regi-
men attributes, such as the number of daily pills, frequency 
and timing of doses, dietary restrictions, adverse events, 
medication storage requirements, are seen by patients as 
major factors making adherence difficult to the proposed 
HAART regimen.17,27 Several studies14–18 have explored how 
the reduction of pill burden and/or daily doses could affect 
adherence to antiretroviral regimens. Although the general 
conclusion was that simpler regimens were associated with 
better adherence rates, all these studies presented a common 
bias, as the compared therapies did not differ just for number 
of pills or doses, but were also based on different drugs. 
The confounding effect of different subjective tolerability 
could not, therefore, be ruled out. In this study, for the first 
time, the effect of simply reducing the number of pills in the 
regimen was evaluated in the absence of drug differences, 
assuming lamivudine equivalency (in tolerability terms) to 
emtricitabine.21 This approach was made possible by the use 
of a FDC pill combining all the drugs previously taken by 
our patients as separated entities.
Despite the fact that the study population comprised 
highly adherent patients, virologically responding to HAART, 
by simply reducing the number of pills of the therapeutic 
regimen, we obtained a significant increase in adherence that 
was maintained throughout the study period. It is known that 
self-reported adherence values may be higher, in absolute 
terms, than those derived with other measurement methods 
(ie, unnnounced pill counts or MEMS);9 however, because 
our data were comparable within the same patients and 
obtained by the same measurement method, their relative 
validity is maintained.
The observed increase at the end of follow-up was 
between 0.6% and 1.1% considering 1-month or 1-week 
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recall, and between 2.3% and 2.4% considering dosing 
 intervals. Although not large in absolute terms, these differ-
ences should be regarded as clinically meaningful, especially 
considering the direction of change.28 In fact, for adherence 
rates with respect to dose timing, the observed increases 
induced mean values always superior to the 95% (lower limit 
of 95% CI above 94%) threshold, a limit often regarded as 
safe in terms of virologic efficacy of HAART.4,29,30
A substantial proportion of subjects in our study reported 
adverse symptoms caused by, or suspected by patients to 
be a result of, antiretroviral therapy. The average discom-
fort/intensity caused by these symptoms, as reported by 
patients, was generally low and patients would not even have 
reported their occurrence to the care-givers if not actively 
questioned about it. However, it has been demonstrated that 
the presence of these symptoms is associated with intentional 
non-adherence31 and that patients’ experience or fear of pos-
sible AEs is an important cause of reduced adherence.32 The 
presence and number of symptoms significantly affected 
perception of health status and, as already described,33 
self-reported QoL, with QoL being inversely related to the 
number of symptoms. The reduction in the proportion of 
subjects reporting any subjective symptom and the reduction 
in the number of symptoms we observed after the switch 
to the FDR-based HAART paralleled the increased in self-
reported QoL.
Perceived QoL was significantly associated with self-
reported adherence, with patients in higher QoL percentiles 
showing better adherence rates. The difference was more 
pronounced when both the number and timing of doses 
concurred in defining the adherence rate. In this case being 
above the 50 percentile consistently assured adherence 
rates 95%. The increase in QoL observed after a therapeutic 
switch (3.9%) could therefore play a relevant role in assuring 
better adherence and, as a consequence, long-term virologic 
efficacy of HAART.
The virologic efficacy of the FDR-based HAART was 
high. After 6 months of therapy 98% of patients still presented 
a HIV-RNA level 50 copies/mL (as treated population). 
Furthermore, all viral load increases observed were spo-
radic, of low intensity, and were not confirmed in successive 
samples. Because our patients were on an effective HAART 
for a long period of time, the release of virus from latently 
infected reactivated CD4 cells, rather than an ongoing viral 
replication, could be a likely explanation of these findings.34 
This possible explanation is supported by the adherence 
rates reported by patients presenting viral blips, which did 
not differ and were even higher than those of patients with 
complete control of viral replication, and by the observation 
that 100% of patients on HAART presented a viral load 
400 copies/mL. The high virologic efficacy observed while 
patients took the FDC-based HAART does not allow us to 
quantify the role of adherence on this outcome measure, 
but it is highly probable that enhanced adherence positively 
influenced this result.
The absence of a parallel control group does not allow 
us to quantify the role of switching therapy on the observed 
increase in CD4 T-cell counts. However, the increase was 
highly statistically significant and was observed at any time 
point of the follow-up period, indicating a constant positive 
effect of HAART on immunological response. This finding 
is in contrast with previously reported results with the FDC-
based HAART.35
Four possible limitations to this study warrant specific 
mention. First, we were unable to define refusal rates, because 
data on potential participants to the study were not collected if 
patients were not interested. However, the demographic char-
acteristics of enrolled patients are representative of the popu-
lation of HIV-infected patients currently assuming HAART in 
Italy, providing some reassurance that our sample is represen-
tative of the population of interest. Second, trials that involve 
switching strategies tend to attract patients already motivated 
to make a change in treatment. As a consequence a possible 
intrinsic bias toward favoring the switch option under evalu-
ation may be present. The motivation to simplify therapy in 
this stable population could have affected patients’ reporting 
of investigated variables such as the occurrence of specific 
symptoms or adherence rates and/or medication preferences. 
However, over time, patients’ consistency in reporting and 
grading AEs, adherence rates, QoL items, and therapeutic 
preferences was very high. An intentional reporting bias is 
therefore highly improbable, although psychological influ-
ences on the individual judgement cannot be excluded. Third, 
we chose an open-label design with intra-patient control 
(evaluating pre/post repeated measures with paired tests). 
Although this trial design has some limitations, its choice was 
based on several methodological considerations. The open-
label was the only possible option to evaluate the effect of 
pill reduction on outcome measures. The absence of a parallel 
control group did not allow for some inferential analysis, but 
did not introduce possible evaluation bias associated with 
higher drop-out rates in the control group35 determined by a 
desire to obtain the simpler regimen. Fourth, as the Italian 
health care system provides completely free-of-charge assis-
tance and therapy to HIV-infected individuals, we did not 
include economic issues in the evaluation of health-related 
Patient Preference and Adherence 2010:4124
Airoldi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
QoL. In other social settings where co-payments or private 
insurance fees are due, such variables could have a relevant 
effect on perceived QoL.36
Finally, when asked about regimen preferences, patients 
indicated the FDR-based HAART as highly preferable in 
terms of simplicity, convenience and tolerability. It is highly 
probable that patients’ expectations and psychological 
motivations to simplify HAART did influence their judg-
ment especially if we consider that the same preference was 
expressed in term of potency. However, it must be noted that 
patients previously treated with lamivudine and thus receiving 
a regimen based on 3 pills reported a higher preference rate 
for the FDC than those treated with emtricitabine who were 
on a previous HAART based on 2 pills because of the use 
of the emtricitabine/tenofovir combination. This difference 
was constant over time and was reported for all the inves-
tigated characteristics. Although not statistically significant 
(the study was not powered to detect such a difference) this 
observation clearly shows how even minimal simplifica-
tions are preferred by patients. In any case, we believe that 
patients’ perception, rather than rational judgment, should be 
considered in evaluating these choices, as patients’ perception 
may act as a trigger to make HAART more acceptable and 
to favor persistence on therapy.
In summary, this study confirms the high antiviral activity 
and tolerability of a single-pill HAART simplification 
 strategy based on the use of a FDC containing emtricitabine, 
tenofovir and efavirenz. For the first time the crude effect of 
reducing the number of pills on adherence has been evaluated 
and results confirm that simpler regimens are associated 
with higher adherence rates, as well as improvement in 
QoL. Better adherence, high QoL and enhanced patients’ 
preferences are all variables which might combine to assure 
long-lasting efficacy of HAART.
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